Itci stock zacks
Check out our ITCI stock analysis, current ITCI quote, charts, and historical prices for Intra-Cellular Ther stock Zacks Investment Research upgraded shares of Intra-Cellular Therapies (NASDAQ:ITCI) from a hold rating to a buy rating in a research report report published on Wednesday, Zacks.com reports. Zacks Investment Research currently has $13.00 price target on the biopharmaceutical company’s stock. Intra-Cellular Therapies Stock Price, Chart, Latest News, Technical Indicator and other information 10/13/2019 · Zacks Investment Research upgraded shares of Intra-Cellular Therapies (NASDAQ:ITCI) from a hold rating to a strong-buy rating in a research report released on Wednesday, Zacks.com reports. The firm currently has $9.25 price objective on the biopharmaceutical company’s stock. 12/16/2019 · Interactive Chart for Intra-Cellular Therapies Inc. (ITCI), analyze all the data with a huge range of indicators. 2/26/2018 · Intra-Cellular Therapies (ITCI) initiated with Overweight rating and $25 (28% upside) price target at JPMorgan. Intec Pharma (NTEC) initiated with Buy rati Intra-Cellular Therapies News: This is the News-site for the company Intra-Cellular Therapies on Markets Insider
12/24/2019 · Moving Average Crossover Alert: Intra-Cellular Therapies. Intra-Cellular Therapies, Inc. (ITCI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
KBR Downgraded to Strong Sell on Disappointing Q2 Results - Analyst Blog On Aug 13, Zacks Investment Research downgraded KBR, Inc. ( KBR ) to a Zacks Rank #5 (Strong Sell) from Zacks Rank #4 (Sell) largely due to dismal second quarter 2014… Zacks Rank #1 Addition for Monday - Tale of the Tape Here are 5 stocks added to the Zacks Rank #1 ("strong buy") List today: 1st United Bancorp Inc. ( FUBC ) Advent Software, Inc. ( ADVS ) Aeroflex Holding Corp. ( ARX ) Agenus Inc. ( AGEN… The Zacks Analyst Blog Highlights: Delta Air Lines, American Airlines Group, United Continental Holdings, Republic Airways and Alaska Air Group - Press Releases For Immediate Release Chicago, IL March 13, 2015 Zacks.com announces the list… Stock Briefly Dropped Today What MannKind Corp .'s stock briefly fell by 11% today after its marketing partner Sanofi reported its second quarter sales for the inhaled insulin product Afrezza. MEMP Added as Top 10 Energy Dividend Stock With 12.63% Yield Memorial Production Partners LP (Symbol MEMP) has been named as a Top 10 dividend paying energy stock, according to Dividend Channel , which published its weekly ''DividendRank…
17 Dec 2019 Intra-Cellular Therapies Inc (NASDAQ:ITCI) saw unusually large options set a $9.50 price target on the stock in a research note on Thursday,
3 Reasons Why Intra-Cellular Therapies (ITCI) is a Great Momentum Stock. September 11, 2017, 08:56:00 AM EDT By Zacks.com. Shutterstock photo. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group. TheStreet Ratings updates stock ratings daily.
ITCI Stock News and Research Articles - Intra-Cellular Therapies : latest news, headlines and research articles.
26 Dec 2019 Zacks Investment Research lowered shares of Cal-Maine Foods Corp Trims Position in Intra-Cellular Therapies Inc (NASDAQ:ITCI) Finally, Stephens set a $45.00 price objective on Cal-Maine Foods and gave the stock a 17 Dec 2019 Intra-Cellular Therapies Inc (NASDAQ:ITCI) saw unusually large options set a $9.50 price target on the stock in a research note on Thursday, 2 days ago Intra-Cellular Therapies Inc (NASDAQ:ITCI) was the target of a $21.00 target price on shares of Intra-Cellular Therapies and gave the stock a View Intra-cellular Therapies Inc. ITCI investment & stock information. Get the latest Intra-cellular Therapies Inc. ITCI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Intra-cellular Therapies Inc. - ITCI - Stock Price Today - Zacks
Going by the Zacks model, companies holding a Zacks Rank #4 have high chances of underperforming
National Bankshares: A Strong Buy - Analyst Blog On Mar 6, Zacks Investment Research upgraded National Bankshares Inc. ( NKSH ) to Zacks Rank #1 (Strong Buy). LNB Bancorp Upped to Strong Buy - Analyst Blog On Mar 28, Zacks Investment Research upgraded LNB Bancorp Inc. ( LNBB ) to a Zacks Rank #1 (Strong Buy).Why the Upgrade? With this, earnings beat the Zacks Consensus Going by the Zacks model, companies holding a Zacks Rank #4 have high chances of underperforming Zacks Rank #5 Additions for Tuesday - Tale of the Tape Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today Abaxis Inc ( ABAX )AK Steel Holding Corporation ( AKS )American Capital Mortgage Investment Crp ( MTGE )Atlantic…
Intra-Cellular Therapies Inc. lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 75.08% during the next 3 months and, with 90% probability hold a price between $24.66 and $69.31 at the end of this period. Intra-Cellular Therapies (NASDAQ:ITCI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Thursday, Zacks.com reports. The firm presently has a $9.50 price objective on the biopharmaceutical company’s stock. Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options. 06-17 zacks.com - 1 Investors in Intra-Cellular Therapies, Inc. (ITCI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 21, 2019 $10 Put had some of the highest implied volatility of all equity options